Goldman Sachs Group began coverage on shares of SpringWorks Therapeutics (NASDAQ:SWTX) in a research report report published on Tuesday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $37.00 target price on the stock.
A number of other research firms have also recently issued reports on SWTX. Cowen started coverage on SpringWorks Therapeutics in a research report on Tuesday. They issued an outperform rating on the stock. JPMorgan Chase & Co. started coverage on SpringWorks Therapeutics in a research report on Tuesday. They issued an overweight rating and a $32.00 target price on the stock. Finally, Wedbush started coverage on SpringWorks Therapeutics in a research report on Tuesday. They issued an outperform rating and a $33.00 target price on the stock.
SpringWorks Therapeutics stock opened at $18.96 on Tuesday. SpringWorks Therapeutics has a 12-month low of $17.66 and a 12-month high of $28.62.
SpringWorks Therapeutics Company Profile
SpringWorks Therapeutics, Inc, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its advanced product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase 3 clinical trials for the treatment of desmoid tumors.
Featured Story: What is a price target?
Receive News & Ratings for SpringWorks Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SpringWorks Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.